In a significant milestone for the advancement of intelligent transport systems, representatives from fifteen partner institutions converged in the Swiss city of Winterthur for the General Assembly of the MOVEO project. Spanning two days in early June and hosted collaboratively by the Zurich University of Applied Sciences (ZHAW) alongside the City of Winterthur, this high-level meeting marked a pivotal moment to assess the multifaceted progress achieved in this ambitious European Union-backed initiative. The assembly provided a platform for experts specializing in transport infrastructure, digitalization, and inclusivity to engage in comprehensive dialogues surrounding the integration of cutting-edge technologies across diverse transport environments.

MOVEO stands at the intersection of innovation and real-world application, targeting critical challenges faced by modern transport systems. Over the course of the assembly, attendees delved deeply into advancements across the project’s core technical domains. One focal area involved the enhancement of inspection and monitoring systems designed to surveil transport infrastructure dynamically and track traffic flows in real time. By deploying sophisticated sensors and analytic devices, the project aims to generate actionable data streams that can preemptively identify structural stresses or anomalies, ultimately elevating maintenance efficiency and passenger safety.

Another crucial theme that permeated discussions was the development of intelligent door-to-door mobility solutions catering to both passenger transit and goods logistics. These smart mobility frameworks integrate multimodal transport options, leveraging data-driven route optimization and seamless transfer protocols to facilitate efficient, sustainable travel. The capacity of such systems to adapt dynamically to user needs and traffic conditions represents a paradigm shift from traditional static schedules to responsive, user-centric mobility networks.

In tandem with technological innovation, a significant portion of the dialogue addressed the pursuit of inclusivity and accessibility within transport services and infrastructure. Realizing transport environments that accommodate the full spectrum of user abilities demands rigorous design principles and thoughtful integration of assistive technologies. MOVEO’s commitment to these objectives manifests in both hardware adaptations and software interfaces, ensuring equitable access and enhancing user experience for disabled individuals, elderly passengers, and other traditionally underserved demographics.

Central to MOVEO’s methodology is the concept of a ‘digital twin’—a sophisticated virtual replica of physical assets and operational scenarios. This digital twin platform supports the project’s demonstration sites by enabling detailed simulation, predictive modeling, and real-time monitoring in a highly scalable and flexible manner. The ability to virtually recreate and experiment within these models accelerates technology validation cycles and informs better decision-making, reducing costs and mitigating risks associated with physical trial-and-error processes.

Highlighting the project’s real-world applicability, the partners provided updates on progress across five geographically and climatically diverse demonstration sites. Two are situated in eastern Switzerland, reflecting alpine and temperate conditions, while the others span the historic landscape of Ravenna, Italy; the complex hydrological system of France’s Seine basin; and the strategic maritime hub of Klaipėda port in Lithuania. Each site serves as a living laboratory where varying infrastructure types and life cycle stages are addressed, allowing the consortium to benchmark technologies against multifaceted operational contexts.

During the assembly, a notable field visit to the Leonie-Moser bridge in Winterthur offered tangible insight into the ongoing integration of MOVEO innovations. This upcoming bridge, slated for completion in September 2026, will link the districts of Oberwinterthur and Grüze, facilitating pedestrian and bus transit. Importantly, it forms a key node for sensor installations dedicated to monitoring passenger flows, particularly as commuters transfer between train and bus services. The instrumentation strategy exemplifies how real-time data acquisition enables nuanced understanding of multimodal transport interactions on critical infrastructure.

José Solís Hernández, project coordinator and an expert engineer from Spain’s CEMOSA, underscored the rapid progress being made in technological implementations. Reflecting on the trajectory thus far, Hernández emphasized the consortium’s focus on concluding key installation phases by the upcoming October deadline. This timeline aligns with preparatory activities for the next formal project review, during which minimum viable products (MVPs) must be finalized, demonstrating functional readiness and alignment with strategic objectives.

MOVEO’s expansive consortium harnesses expertise from nine European nations, uniting a comprehensive value chain that spans the entirety of transport and digitalization disciplines. The collective includes specialists in critical areas such as structural inspection, advanced monitoring techniques, logistics optimization, user mobility dynamics, and social inclusiveness. Engaging end-users alongside transport infrastructure managers ensures that developed solutions remain relevant, practical, and attuned to operational realities.

The innovative research underpinning MOVEO crystallizes around five core pillars. Firstly, infrastructure assessment and redesign leverages analytical tools to evaluate existing assets, proposing modifications that enhance resilience and adaptability. Secondly, inspection and monitoring integrate sensor networks and diagnostic technologies to maintain operational integrity. The third pillar, digitalized mobility, focuses on user-centered, data-driven solutions that redefine transit experiences. Smart logistics form the fourth pillar, addressing the efficient movement of goods with a sustainability lens. Finally, inclusiveness and accessibility aim to democratize mobility services, ensuring no user is left behind regardless of physical or cognitive barriers.

Backed by nearly five million euros in funding through the European Union’s Horizon Europe framework, MOVEO is positioned for a 42-month research phase culminating in October 2028. This substantial financial support reflects the high strategic importance assigned to the project, especially amidst rising pressures to modernize transport infrastructure in alignment with environmental, economic, and social objectives. The collaborative approach fosters cross-border innovation, ensuring outcomes deliver broad-reaching impacts for European mobility systems and beyond.

Ultimately, MOVEO exemplifies how integrative, interdisciplinary research can be effectively mobilized to tackle the complexities of future transport demand. By bridging digital technology with physical infrastructure and emphasizing user inclusivity, the project charts a course toward a smarter, safer, and more sustainable mobility ecosystem. As installations near completion and the demonstrator sites become fully operational, MOVEO’s innovations promise to inform policy, guide industry practices, and elevate standards across the entire European transportation landscape.

Subject of Research: Transport infrastructure monitoring, digitalized mobility, and inclusive transport solutions in Europe.

Article Title: (Not provided)

News Publication Date: (Not provided)

Web References: https://mediasvc.eurekalert.org/Api/v1/Multimedia/27a1c0f0-d8a7-487e-97b3-ebce96f60ef7/Rendition/low-res/Content/Public

References: (Not provided)

Image Credits: European Science Communication Institute gGmbH

Keywords: MOVEO project, transport infrastructure, digital twin, sensor monitoring, multimodal mobility, smart logistics, transport inclusiveness, European Union Horizon Europe, infrastructure assessment, pedestrian flow monitoring

In a groundbreaking study poised to redefine cancer immunotherapy paradigms, researchers have unveiled a programmable RNA engineering platform that restores immune recognition in notoriously immune-resistant tumors such as prostate cancer. This innovative approach, centered on precise manipulation of mRNA alternative polyadenylation (APA), revives the expression of major histocompatibility complex class I (MHC-I) molecules — the pivotal sentinels of immune surveillance routinely downregulated in these tumors. The findings, detailed in Nature Biomedical Engineering, shed light on an elusive molecular mechanism of immune evasion and herald a new frontier in translational cancer immunology.

Prostate cancer and analogous immune-cold tumors have long bedeviled clinicians by resisting immune checkpoint inhibitor therapies, a frontline strategy in modern oncology. A primary culprit in this resistance is the diminished presentation of tumor-specific antigens on MHC-I molecules, molecules intrinsically responsible for flagging abnormal cells to cytotoxic CD8 T cells. Without adequate MHC-I display, these malignant cells evade immune detection, rendering checkpoint blockade largely ineffective. Despite the clinical significance, no therapies have yet emerged that selectively restore MHC-I expression, underscoring a critical unmet medical need.

The investigative team addressed this gap by engineering the 3′UTR CRISPR/dCas13 system (3′UTRCES), an advanced RNA-editing platform designed to modulate mRNA 3′ untranslated region (3′UTR) dynamics in vivo. Unlike conventional gene editing tools that alter DNA sequences, 3′UTRCES uniquely targets RNA transcripts’ polyadenylation sites to manipulate APA patterns — a post-transcriptional regulatory mechanism influencing mRNA stability, localization, and translation. Leveraging a catalytically inactive Cas13 (dCas13) fused to programmable effectors, this system reprograms 3′UTR architecture to reinstate normal gene expression profiles critical for immune function.

Central to their discovery is the identification of tumor-specific 3′UTR shortening in the E3 ubiquitin ligase adaptor SPSB1, a molecular player hitherto not linked to immune modulation. Through sophisticated analyses, the researchers demonstrated that aberrant SPSB1 3′UTR truncations promote enhanced ubiquitination and subsequent degradation of MHC-I molecules. This selective downregulation disrupts the immune system’s ability to recognize and eliminate malignant cells without affecting programmed death-ligand 1 (PD-L1), an immune checkpoint protein. These insights decode a novel mechanism by which tumors suppress antigen presentation, bypassing immune control.

Armed with this mechanistic understanding, the team deployed lipid nanoparticle (LNP) delivery of the 3′UTRCES constructs directly into syngeneic mouse models harboring prostate tumors. This therapeutic intervention reversed the aberrant SPSB1 3′UTR shortening, effectively restoring MHC-I expression on tumor cells. The restored antigen presentation reinvigorated the infiltration of CD8 cytotoxic T lymphocytes, amplifying antitumor immune responses and sensitizing tumors to subsequent immune checkpoint therapies. This combinatorial strategy outperformed existing modalities, offering a tangible path to overcome immune resistance.

The implications of this study extend beyond prostate cancer, representing a conceptual shift in targeting post-transcriptional gene regulation to modulate tumor immunity. By precisely tailoring RNA isoforms through 3′UTRCES, it becomes feasible to rectify pathological gene expression patterns without permanent genomic alterations, minimizing off-target effects and paving the way for tunable, reversible therapies. This technological stride potentially positions LNP-3′UTRCES as a versatile platform for broad-spectrum cancer immunotherapy.

Delving deeper into the molecular underpinnings, the research highlights how alternative polyadenylation — once considered a subtle nuance of gene regulation — plays an outsized role in immune evasion. APA events that truncate key regulatory 3′UTRs can rewire protein expression profiles, impacting ubiquitin-mediated degradation pathways. In SPSB1’s case, 3′UTR shortening shields MHC-I from stable expression, underscoring the delicate interplay between RNA processing and immune visibility. These revelations chart a new investigative avenue for uncovering APA-driven oncogenic mechanisms.

The study harnessed state-of-the-art transcriptomic and proteomic methodologies to validate the APA signatures and subsequent functional outcomes. Single-cell RNA sequencing and cross-linking immunoprecipitation unveiled the precise RNA-protein interactions modulated by 3′UTR alterations. Meanwhile, in vivo tumor growth assays meticulously quantified the therapeutic efficacy of 3′UTRCES-mediated intervention. The robust experimental design marries molecular biology with immuno-oncology, reinforcing the translational promise of RNA engineering.

Beyond prostate cancer, the researchers posit that similar APA-driven immune escape mechanisms may underpin resistance in other malignancies characterized as immune-cold or immunologically excluded. Tumor heterogeneity presents obstacles, yet the adaptability of the 3′UTRCES platform offers a pathway to customize RNA editing interventions tailored to tumor-specific APA landscapes. This precision medicine approach aligns with emerging oncology paradigms striving to unify genetic and epigenetic therapeutic targeting.

Crucially, this work confronts a longstanding conceptual bottleneck — the absence of clinically viable modalities to restore MHC-I expression selectively. Immune checkpoint inhibitors, though transformative, rely heavily on intact antigen presentation machinery to elicit durable responses. By restoring the tumor’s antigen-presenting capacity, 3′UTRCES synergizes with immune checkpoint blockade, reinvigorating exhausted cytotoxic T cells and promoting tumor clearance. This paradigm underscores the importance of targeting upstream immune suppression pathways in cancer.

The LNP delivery mechanism employed is equally noteworthy, showcasing advances in nanomedicine that enable precise nucleic acid transport to tumor sites. Lipid nanoparticles offer biocompatibility, customizable surface chemistry, and efficient endosomal escape — attributes critical for clinical translation. As the field gravitates toward RNA-based therapeutics post-COVID-19, leveraging these delivery systems in oncology sets a precedent for future innovations combining synthetic biology and immunotherapy.

Looking ahead, the scalability and safety of 3′UTRCES-mediated therapies warrant thorough exploration through preclinical and clinical studies. Immunogenicity of RNA-guided effectors, off-target RNA interactions, and durability of therapeutic responses remain important considerations. Nevertheless, the current findings provide a compelling proof of concept, invigorating translational research efforts to combat immune escape mechanisms effectively.

This pioneering research not only reframes our understanding of tumor immune evasion but also exemplifies how RNA technology can be harnessed to unlock therapeutic opportunities in recalcitrant cancers. By transforming APA from a molecular signature of immune suppression into a therapeutic target, the study opens vistas for next-generation cancer treatments that restore immune competence at the RNA level. This convergence of molecular biology, immunotherapy, and RNA engineering heralds a new dawn in oncology innovation.

In summary, the programmable editing of mRNA 3′UTRs via the 3′UTRCES platform revitalizes MHC-I expression in prostate tumors, counteracting immune suppression driven by SPSB1-mediated degradation pathways. This novel mechanistic insight, coupled with effective lipid nanoparticle delivery and demonstrated synergy with immune checkpoint inhibitors, marks a transformative advance in overcoming tumor immune resistance. The study exemplifies how precision RNA engineering can recalibrate tumor immunogenicity and redefine therapeutic potentials in cancer treatment.

As research continues to unravel the complexities of RNA-mediated regulation of immune visibility in cancer, the integration of programmable RNA tools like 3′UTRCES with established immunotherapies holds immense promise. These synergistic strategies may soon accelerate the development of personalized cancer therapies designed to circumvent immune escape and foster more durable clinical remissions. The future of oncology may indeed lie at the interface of RNA engineering and immunomodulation.

This landmark work not only elucidates a previously unrecognized molecular mechanism of immune evasion but also delivers a versatile, programmable therapeutic platform for precise post-transcriptional gene regulation in cancer. Its translational implications inspire optimism for expanding the repertoire of RNA-based interventions that can be tailored to diverse tumor contexts, ultimately enhancing patient outcomes and transforming cancer immunotherapy at its molecular roots.

Subject of Research: Programmable RNA engineering to restore MHC-I expression and overcome immune evasion in prostate cancer.

Article Title: Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.

Article References:
Huang, F., Yuan, F., Li, K. et al. Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01720-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01720-9